It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
There is an urgent need for animal models to study SARS-CoV-2 pathogenicity. Here, we generate and characterize a novel mouse-adapted SARS-CoV-2 strain, MASCp36, that causes severe respiratory symptoms, and mortality. Our model exhibits age- and gender-related mortality akin to severe COVID-19. Deep sequencing identified three amino acid substitutions, N501Y, Q493H, and K417N, at the receptor binding domain (RBD) of MASCp36, during in vivo passaging. All three RBD mutations significantly enhance binding affinity to its endogenous receptor, ACE2. Cryo-electron microscopy analysis of human ACE2 (hACE2), or mouse ACE2 (mACE2), in complex with the RBD of MASCp36, at 3.1 to 3.7 Å resolution, reveals the molecular basis for the receptor-binding switch. N501Y and Q493H enhance the binding affinity to hACE2, whereas triple mutations at N501Y/Q493H/K417N decrease affinity and reduce infectivity of MASCp36. Our study provides a platform for studying SARS-CoV-2 pathogenesis, and unveils the molecular mechanism for its rapid adaptation and evolution.
In this study, Qin et al. present a murine-adapted SARS-CoV-2 strain, MASCp36, as a model for studying the pathogenicity, evolution and adaptation of the virus to human and animal hosts.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details










1 Beijing Institute of Microbiology and Epidemiology, AMMS, State Key Laboratory of Pathogen and Biosecurity, Beijing, China (GRID:grid.410740.6) (ISNI:0000 0004 1803 4911)
2 Chinese Academy of Sciences, CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Beijing, China (GRID:grid.9227.e) (ISNI:0000000119573309)
3 Beijing Institute of Lifeomics, State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing, China (GRID:grid.419611.a) (ISNI:0000 0004 0457 9072)
4 Chinese Center for Disease Control and Prevention (China CDC), National Institute for Viral Disease Control and Prevention, Beijing, China (GRID:grid.198530.6) (ISNI:0000 0000 8803 2373)
5 Tsinghua University, The Ministry of Education Key Laboratory of Protein Science, Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, Collaborative Innovation Center for Biotherapy, School of Life Sciences, Beijing, China (GRID:grid.12527.33) (ISNI:0000 0001 0662 3178)
6 Beijing Institute of Microbiology and Epidemiology, AMMS, State Key Laboratory of Pathogen and Biosecurity, Beijing, China (GRID:grid.410740.6) (ISNI:0000 0004 1803 4911); Chinese Academy of Medical Sciences, Research Unit of Discovery and Tracing of Natural Focus Diseases, Beijing, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839)